The Jerusalem Post:
Moderna Inc applied for European authorization of its COVID-19 vaccine in children aged 6-11 years, weeks after it delayed a similar filing with US regulators.
France’s public health authority has recommended people under 30 be given Pfizer’s Comirnaty COVID-19 vaccine when available instead of Moderna’s Spikevax jab, which carried comparatively higher risks of heart-related problems.
The Haute Autorite de Sante (HAS), which does not have legal power to ban or license drugs but acts as an advisor to the French health sector, cited “very rare” risks linked to Myocarditis, a heart disease, that had shown up in recent data on the Moderna vaccine and in a French study published on Monday.”Within the population aged under 30, this risk appears to be around five times lesser with Pfizer’s Comirnaty jab compared to Moderna’s Spikevax jab,” HAS said in its opinion published on Monday.
The decision in Paris came after regulators in several other countries, including Canada, Finland and Sweden, had also taken a more defensive stance on Spikevax over heart-related safety concerns affecting younger people.The European Union’s drug regulator EMA last month approved Moderna’s booster vaccine for all age groups over 18, at least six months after the second dose.